What exactly did William Blair change for Exagen on March 10, 2026?

William Blair maintained an **Outperform** rating on **March 10, 2026** at 12:19 PM. The firm reiterated its positive view after Q4 results but did not issue a new price target.

How should I interpret the XGN analyst rating for trading decisions?

A maintained Outperform means continued analyst confidence without fresh bullish proof. Use it alongside company catalysts, liquidity, and Meyka’s grade when sizing trades.

Did the William Blair note include a new XGN price target?

No. The March 10, 2026 William Blair note reiterated the Outperform rating but did not publish a new **XGN price target** in the StreetInsider summary.

What is Meyka AI’s view and grade for XGN?

Meyka AI rates XGN with a grade of **B**. This grade factors S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus.

Analyst Ratings

William Blair Maintains Outperform on Exagen Inc. (XGN) March 2026

ByDanny Kontos March 11, 2026March 11, 2026

William Blair maintained an Outperform rating on Exagen Inc. (XGN) on March 10, 2026 after the company’s Q4 report. This XGN analyst rating note came at 12:19 PM and followed management commentary on revenue and R&D trends. The firm did not publish a new price target. The market reacted with a -3.29% ($-0.11) move on the day. Market cap $73,655,072 provides scale context for investors tracking analyst flows.